期刊文献+

齐拉西酮注射液治疗精神分裂症激越症状的研究 被引量:16

A study of intramuscular ziprasidone and haloperidol in treating acute agitation in schizophrenia
暂未订购
导出
摘要 目的本研究应用氟哌啶醇注射液作为对照,评价齐拉西酮注射液治疗精神分裂症激越患者的疗效、安全性和耐受性。方法连续入组急性精神分裂症患者,按照1:1的比例随机分配到齐拉西酮注射液治疗组(试验组)和氟哌啶醇注射液治疗组(对照组),对患者进行筛选访视、基线访视,以及肌注治疗第一剂药后的2、4、24、48h和72h的访视。采用简明精神评定量表(BPRS)评价主要疗效,Simpson-Angus量表评定药物的锥体外系反应。结果两组均纳入受试者30例。药物治疗72h后与基线比较,试验组BPRS总分减分平均为12.55±6.88,对照组BPRS总分减分平均为15.60±5.94。两组主要疗效指标差异无统计学意义(P=0.110)。试验组未见锥体外系不良反应,Simpson-Angus量表评分在治疗前后差异无统计学意义(P=0.16);对照组出现锥体外系不良反应,治疗前后差异有统计学意义(P=0.02)。结论甲磺酸齐拉西酮注射液能够快速有效控制精神分裂症急性激越症状,疗效与氟哌啶醇注射液相当,不良反应轻微,安全性、耐受性好,值得临床推广应用。 Objective To explore the efficacy,safety and tolerance of intramuscular ziprasidone for acute agitation in Chinese schizophrenia patients contrasting with haloperidol injection.Methods The acute schizophrenia patients were enrolled consecutively.They were randomly assigned to the intramuscular ziprasidone treatment group (experimental group) and haloperidol injection treatment group (control group) with the ration of 1:1.Study visits included screening visit,baseline visit,as well as 2,4,24,48 and 72-hour point of visit after the first dose was injected.BPRS were used to assess the primary efficacy of these drugs.According to Simpson-Angus Scale,the drugs' adverse event of extra pyramidal symptoms (EPS) were assessed.Results Experimental group and control group both enrolled 30 cases.72 hours after treatment,compared with baseline,experimental group lowered BPRS total score by an average of 12.55 ±6.88,while control group lowered BPRS total score by an average of 15.60 ±5.94.The primary effect of the two groups had no significant difference (P=0.110).For Simpson-Angus Scale score,there was no significant difference between the experimental group before and after treatment (P=0.16).The control group had extrapyramidal side effects,and the difference was statistically significant (P=0.02) before and after treatment.Conclusion Ziprasidone mesylate injection can be as effective as haloperidol injection in the treatment of schizophrenia by rapidly and effectively control acute agitation symptoms.Its adverse reactions are minor and has no extrapyramidal side effects.Ziprasidone injection is effective,safe and well tolerated for schizophrenia patients with agitation symptoms and is worthy of clinical application.
作者 尹析凡 王刚
出处 《中国当代医药》 2012年第30期9-11,共3页 China Modern Medicine
关键词 齐拉西酮注射液 氟哌啶醇注射液 精神分裂症 激越症状 Ziprasidone injection Haloperidol injection Schizophrenia Agitation symptoms
  • 相关文献

参考文献11

  • 1Lesem MD,Zajecka JM,Swift RH,et al. Intramuscular ziprasidone 2 mg versus 10 mg in the short-term management of agitated psychotic pa- tients[J]. J Clin Psychiatry ,2001,62( 1 ) : 12-21.
  • 2Zimbroff DL,Brook S,Benattia I. Safety and tolerability of IM ziprasi- done:review of clinical trial data[C]. Presented at the 155th Annual Meet- ing of the American Psychiatric Association, 2002.
  • 3Brook S ,Lucey JV,Gunn KP. Intrumuscular Ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis[J]. J Clin Psy- chiatry, 2000,61 ( 12 ) : 933 -941.
  • 4Daniel D,Brook S,Benattia I. Transition from IM to oral ziprasidone: Clinical efficacy and safety data[C]. Presented at the 155th Annual Meet- ing of the American Psychiatric Association, 2002.
  • 5Danil DG, Potkin SG, Reeves KR, et al. Intramuscular Ziprasidone 20mg is effective in reducing acute agitation associated with psychosis :a dou- ble blind,randomized trial[J]. J. Psychopharmacology ,2001,155 (2) : 128- 134.
  • 6Keck PE,Versiani M,Potkin S, et al. Intramuscular Ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis [J]. J. Clin Psychiatry, 2000,61 ( 12 ) : 933-941.
  • 7Vieweg WV, Hasnain M. Ziprasidone and QTc Interval Prolongation in the ZODIAC Study[J]. The American Journal of Psychiatry,2011,168(6) : 650-651.
  • 8Strom BL, Eng SM, Faich G, et al. Comparative Mortality Associated with Ziprasidone and Olanzapine in Real-World use Among 18,154 Patients with schizophrenia[J]. The American Journal of Psychiatry, 2011,168 (2) : 193 -201.
  • 9张疆莉,张建宏,申彪.齐拉西酮注射液与氟哌啶醇注射液治疗急性精神分裂症的疗效及安全性比较[J].中国现代药物应用,2010,4(12):126-127. 被引量:13
  • 10何俊,王玉文,王泽民.齐拉西酮研究进展[J].医药导报,2011,30(12):1613-1616. 被引量:12

二级参考文献52

共引文献62

同被引文献102

  • 1卢殿军,宁洁,钟晓妮.甲磺酸齐拉西酮注射液治疗精神分裂症急性激越症状的临床评价[J].中国药业,2006,15(4):48-49. 被引量:8
  • 2李华芳,谢世平,李鸣,张明廉,李静,苏炳华,顾牛范.齐拉西酮治疗精神分裂症的随机、双盲、双模拟、多中心研究[J].中国新药与临床杂志,2006,25(10):747-752. 被引量:69
  • 3李乐华,赵靖平,许秀峰,蒙华庆,宁洁.国产齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的对照研究[J].中华精神科杂志,2006,39(4):216-219. 被引量:51
  • 4沈渔邨.精神病学[M].第6版.北京:人民卫生出版,1996:574.
  • 5沈渔邮主编.精神病学.人民卫生出版社,2009,446-448.
  • 6Zimbroff D L,Brook S, Benattia I. Safety and tolerability of IM ziprasi- done:review of clinical trial data[ C ]. Presented at the 155th Annual Meeting of the American Psychiatric Association,2002:231 - 234.
  • 7Brook S, Lucey J V, Gunn K P. Intramuscular Ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis [ J ]. J Clin Psychiatry ,2000,61 ( 12 ) :933 - 941.
  • 8Simpsonf G M, Glicks I D, Weidenf P J, et al. Randomized, controlled, double - blind muhicenter comparison of the efficacy and tolerabi|ity of zi- prasidone and olanzapine in acutely i|l inpatients with schizophrenia or schizoaffective disorder[ J ]. Am J Psychiatry ,2004,161 : 1837 - 1847.
  • 9semyak M J ,Griffin R A ,Johnson R M ,et al. Neuro|eptic exposure follow- ing inpatical treatment of acute manic with lithium and neuroleptic [ J ]. Am J Psychiatry, 1994,151 : 133 - 136.
  • 10Zimbroff D L, Brook S, Benattia I. Safety and tolerability of IM ziprasi- done:review of clinical trial data [ C ]. Presented at the 155th Annual Meeting of the American Psychiatric Association,2002:231 - 234.

引证文献16

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部